Abstract
1539P Efficacy and safety of perioperative chemotherapy combined with tislelizumab and trastuzumab for HER2-positive resectable gastric/gastroesophageal junction cancer (GC/EGJC): Preliminary results of a phase II, single-arm trial
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have